The role of Frailty on Adverse Outcomes Among Older Patients with COVID-19
Copyright © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: Diagnosis and screening of frailty, a condition characterized by an increased vulnerability to adverse outcomes of COVID-19, has emerged as an essential clinical tool which is strongly recommended by healthcare providers concerned with hospitalized elderly population. The data showing the role of frailty in patients infected with COVID-19 is needed.
METHODS: This was a nationwide cohort study conducted at all hospitals in Turkey. All COVID-19 hospitalized patients (≥ 65 years) were included. Patients who were alive and not discharged up to July 20, 2020, were excluded. The frailty was assessed by using the "Hospital Frailty Risk Score" (HFRS). Patients were classified into three risk groups of frailty based on previously validated cut points as low (<5 points), intermediate (5-15 points), and high (>15 points). Additionally, patients who had the HFRS of ≥5 were defined as frail. The primary outcome was in-hospital mortality rates by frailty group.
RESULTS: Between March 11, 2020, and June 22, 2020, a total of 18,234 COVID-19 patients from all of 81 provinces of Turkey were included. Totally, 12,295 (67.4%) patients were defined as frail (HFRS of >5) of which 2,801 (15.4%) patients were categorized in the highest level of frailty (HFRS of >15). Observed in-hospital mortality rates were 697 (12.0%), 1,751 (18.2%) and 867 (31.0%) in low, intermediate and high hospital frailty risk, respectively (p<0.001). Compared with low HFRS (<5), the adjusted odds ratios for in-hospital mortality were 1.482 (1.334-1.646) for intermediate HFRS (5-15) and 2.084; 95% CI, 1.799-2.413 for high HFRS (>15).
CONCLUSIONS: As a claims-based frailty model, the HFRS provides clinicians and health systems, a standardized tool for an effective detection and grading of frailty in patients in COVID-19. A frailty-based tailored management of the older population may provide a more accurate risk categorization for both therapeutic and preventive strategies.
| Errataetall: |
CommentIn: J Infect. 2021 May;82(5):e18-e19. - PMID 33581239 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
The Journal of infection - 81(2020), 6 vom: 08. Dez., Seite 944-951 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kundi, Harun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 07.01.2021 Date Revised 29.03.2024 published: Print-Electronic CommentIn: J Infect. 2021 May;82(5):e18-e19. - PMID 33581239 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2020.09.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315729961 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315729961 | ||
| 003 | DE-627 | ||
| 005 | 20240329235527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2020.09.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM315729961 | ||
| 035 | |a (NLM)33002560 | ||
| 035 | |a (PII)S0163-4453(20)30636-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kundi, Harun |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of Frailty on Adverse Outcomes Among Older Patients with COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.01.2021 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2021 May;82(5):e18-e19. - PMID 33581239 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Diagnosis and screening of frailty, a condition characterized by an increased vulnerability to adverse outcomes of COVID-19, has emerged as an essential clinical tool which is strongly recommended by healthcare providers concerned with hospitalized elderly population. The data showing the role of frailty in patients infected with COVID-19 is needed | ||
| 520 | |a METHODS: This was a nationwide cohort study conducted at all hospitals in Turkey. All COVID-19 hospitalized patients (≥ 65 years) were included. Patients who were alive and not discharged up to July 20, 2020, were excluded. The frailty was assessed by using the "Hospital Frailty Risk Score" (HFRS). Patients were classified into three risk groups of frailty based on previously validated cut points as low (<5 points), intermediate (5-15 points), and high (>15 points). Additionally, patients who had the HFRS of ≥5 were defined as frail. The primary outcome was in-hospital mortality rates by frailty group | ||
| 520 | |a RESULTS: Between March 11, 2020, and June 22, 2020, a total of 18,234 COVID-19 patients from all of 81 provinces of Turkey were included. Totally, 12,295 (67.4%) patients were defined as frail (HFRS of >5) of which 2,801 (15.4%) patients were categorized in the highest level of frailty (HFRS of >15). Observed in-hospital mortality rates were 697 (12.0%), 1,751 (18.2%) and 867 (31.0%) in low, intermediate and high hospital frailty risk, respectively (p<0.001). Compared with low HFRS (<5), the adjusted odds ratios for in-hospital mortality were 1.482 (1.334-1.646) for intermediate HFRS (5-15) and 2.084; 95% CI, 1.799-2.413 for high HFRS (>15) | ||
| 520 | |a CONCLUSIONS: As a claims-based frailty model, the HFRS provides clinicians and health systems, a standardized tool for an effective detection and grading of frailty in patients in COVID-19. A frailty-based tailored management of the older population may provide a more accurate risk categorization for both therapeutic and preventive strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Frailty | |
| 700 | 1 | |a Çetin, Elif Hande Özcan |e verfasserin |4 aut | |
| 700 | 1 | |a Canpolat, Uğur |e verfasserin |4 aut | |
| 700 | 1 | |a Aras, Sevgi |e verfasserin |4 aut | |
| 700 | 1 | |a Celik, Osman |e verfasserin |4 aut | |
| 700 | 1 | |a Ata, Naim |e verfasserin |4 aut | |
| 700 | 1 | |a Birinci, Suayip |e verfasserin |4 aut | |
| 700 | 1 | |a Çay, Serkan |e verfasserin |4 aut | |
| 700 | 1 | |a Özeke, Özcan |e verfasserin |4 aut | |
| 700 | 1 | |a Tanboğa, Ibrahim Halil |e verfasserin |4 aut | |
| 700 | 1 | |a Topaloğlu, Serkan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 81(2020), 6 vom: 08. Dez., Seite 944-951 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2020 |g number:6 |g day:08 |g month:12 |g pages:944-951 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2020.09.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2020 |e 6 |b 08 |c 12 |h 944-951 | ||